upgrad outperform concern
abound valuat attract
share under-perform ytd year
year year period share trade discount peer
teva believ under-perform relat varieti sector
mylan-specif
believ deserv seriou
consider howev long said share
approxim discount consid fair valu
could construct stock share
near discount level believ share posit
near-term out-performance maintain ep
guidanc impli rang vs
consensu estim estim price
target base dcf unchang share
price-to-earnings signific discount peer includ direct peer teva
previous thought risk estim
result believ risk downsid estim
lower previous thought myl statement
guidanc achiev without new approv believ
provid upsid sentiment gener advair
believ share carri higher averag risk especi
given compani histori earn goal includ
reset earn guidanc lower previous year well limit
gener sector secular growth believ govern
execut compens face under-perform share
price also worth consid current ceo took helm
januari sinc share under-perform
percentag point vs
item believ warrant consider includ lower
expect spend adjust earn calcul
special item includ million sale
help get adjust earn relat certain increment
manufactur varianc site remedi activ relat
activ morgantown facil note contrast
million adjust year ago quarter
million special item sale
believ left reader suffici reflect
concern valuat upgrad share
risen alreadi today result believ share
still addit upsid potenti reach fair
valu upgrad outperform
chang cautiou outlook gener fundament rather
simpli differ think fair valu vs
current price upgrad outperform maintain
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
compani data secur llc estim reuter
report adjust ep estim
consensu ep
total revenu declin ex-fx billion estim
consensu billion segment north american revenu declin ex-fx
note implement new account standard also million neg headwind
ex account chang outsid revenu europ flat ex-fx
increas rest world ex-fx north america revenu approxim in-
line expect europ rest world revenu lower model
adjust gross margin improv approxim bp yoy due new product launch
vs expect million vs million estim sg
million vs million estim
substant updat gener advair approv date receiv
approv ceo heather bresch note confer call whenev market form
go import product long period time
strateg review front accord board busi look lot thing
mandat time-frame recommend note previous believ
anyth major come review
total debt end approxim billion ltm ebitda target
leverag compani call expect repay least billion matur debt
year end focu debt pay capit deploy adjust
approxim million billion year-to-d
million except ep
restructur remedi cost quarter implicit add back idea
exclud cost sinc like perman howev seem us
cost incur earlier plant would need remedi
word us compani may overearn spend
play catch per fda competit requir ask
ignor cost suggest investor consid cost serious exclus
cost contribut adjust earn upsid rel expect estim
tax-adjust basi assum tax rate exclus cost may
contribut adjust ep ep beat vs consensu
lastli note spend low approxim consensu
sale sourc better expect earn
factset secur llc estim
million unless otherwis note
compani file factset secur llc estim
previou new incom segment revenu north rest chg segment revenu north rest profit expens expens interest incom incom incom per specialti pharmaceut
price target nc
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like less favor prior
year gener compani may less polit cover go forward gener drug
penetr may alreadi peak epipen concentr sale profit govern risk
sec investig lawsuit integr risk tie meda deal
believ share posit near-term out-performance driven near discount
estim fair valu still cautiou outlook gener fundament like
stock current valuat
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
